DERMAL FILLERS

E.P.T.Q 

E.P.T.Q is a dermal filler line made for individuals who want to perfect the exquisite details of their appearance. The name is derived from the words “Exquisite” and “Technique”. These fillers are based on non-animal cross-linked hyaluronic acid, which provides a polymer network that extends the retention properties of the hyaluronic acid, resulting in a long-lasting product. The E.P.T.Q dermal filler line consists of three products that meet all demands for achieving beautifully sculptured results.

E.P.T.Q has three types of filler; each achieves different looks:

• S100 – Use it for: correction of the forehead, earlobes, crows feet, temples and ear trophs. 

• S300 – Use it for: Lip contouring, lip volume, glabella lines, forehead lines, cheek, chin and nose. 

• S500 – Use it for the correction of age-related changes in skin relief, correction of facial areas with volume deficiency. 

Saypha 

Saypha dermal fillers with S.M.A.R.T technology are designed by the Croma Laboratory. These the new cross-linked hyaluronic acid fillers are sterile, clear, biodegradable, viscoelastic, isotonic and homogenised injectable gel implants. The product is classified as a medical device and is ideal for correcting peri-oral wrinkles, contouring the lips and increasing lip volume. It is also used for reconstruction purposes in the treatment of facial lipoatrophy, scarring or morphological asymmetry. 

Croma offers a complete range of HA fillers:

• Saypha® RICH

• Saypha® FILLER

• Saypha® VOLUME

• Saypha® FILLER Lidocaine

• Saypha® VOLUME Lidocaine

• Saypha® VOLUME PLUS

Proluma

Proluma PLA by Genese Labs France, a cutting-edge natural collagen stimulator designed to rejuvenate skin texture gradually. Unlike traditional PLA fillers, Proluma boasts a unique formulation with perfect spherical shapes and uniform particle size, requiring lower injection power.

Proluma effectively promotes the generation of new tissues and collagen, demonstrating a progressive cellular response to the treatment:

• By Week 2 post-injection, cellular proliferation is evident as cells begin to adhere to the surface of PDLLA particles and occupy the interstitial spaces between them, effectively filling these voids with new tissue growth.

• By Week 8, the previously observed spaces between PDLLA particles no longer exist, having been completely occupied by cells. These cells initiate migration into the porous structure of the PDLLA particles, as indicated by the yellow arrow.

• By Weeks 12 and 20, an advanced stage of cellular integration is observed. Cells have penetrated deeply into the inner regions of the PDLLA particles, thoroughly inhabiting both the internal spaces and the areas between particles, culminating in significant tissue regeneration and volumization.